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Background: Opioids are commonly prescribed to manage pain associated with inflammatory 
bowel disease (IBD). It is unknown what percentage of patients develop new persistent opioid 
use following a steroid-treated IBD flare.  
Abstract 
Aims: We aimed to identify the incidence and the predictors of new persistent opioid use 
following an IBD flare. 
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Methods: We used a national insurance claim dataset to identify patients with IBD who received 
an opioid medication around the time of a corticosteroid-treated IBD flare. Patients were 
stratified as previously opioid naïve, intermittent users, or chronic users. The incidence of 
persistent opioid use among the opioid-naïve cohort was evaluated along with associated 
predictors.  
Results: We identified 15,119 IBD patients who received opioids around the time of a flare. 
5,411 (35.8%) were opioid-naïve patients of which 35.0% developed persistent opioid use after 
the flare. Factors associated with new persistent opioid use include a history of depression 
(hazard ratio [HR] 1.29, 95% confidence interval [CI] 1.13-1.47), substance abuse (HR 1.36, 
95% CI 1.2-1.54), chronic obstructive pulmonary disease (COPD) (HR 1.17, 95% CI 1.04-1.3), 
as well as, Crohn’s disease (HR 1.26, 95% CI 1.14-1.4) or indeterminate colitis (HR 1.6, 95% CI 
1.36-1.88). 
Conclusion: New persistent opioid use is common in IBD patients who experience a flare, 
especially among those with mental health disorders, COPD, and Crohn’s disease or 
indeterminate colitis. These findings can be helpful in risk-stratifying patients when choosing an 
acute pain therapy and providing counselling before choosing to prescribe opioids to opioid-
naïve patients experiencing an IBD flare.  
 
Keywords: 
Inflammatory bowel disease; IBD; flare; opioid; steroid  
 The opioid epidemic related to prescription misuse has been a topic of recent intense 
scrutiny on a national level
Introduction 
1
. The number of opioid prescriptions in the U.S. has increased by 
35% between the years 2002 and 20092. Approximately 15.5 million adult Americans reported 
misusing prescription opioids, and 1.9 million met the diagnostic criteria for opioid prescription 
abuse2. Death resulting from overdosing a prescribed opioid is far greater than is the number of 
fatal overdoses caused by cocaine and heroin combined3-6. It has been shown that chronic opioid 
use is associated with many adverse events including an increased risk of myocardial infarction, 
bowel obstruction, respiratory distress, falls, and fractures7-9. 
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 Inflammatory bowel disease (IBD) flares are characterized by symptoms of abdominal 
and pelvic pain and diarrhoea for which an opioid could be used for symptomatic relief. 
Rheumatologic extra-intestinal manifestations of IBD can be another aetiology of pain in this 
patient population. Pain associated with flares usually subsides following flare resolution; 
however, pain symptoms can persist in the absence of objective evidence of active disease10, 11. 
Worsening abdominal pain with continued or escalating doses of narcotics may manifest as 
narcotic bowel syndrome11. It has been reported that IBD is an independent risk factor for using 
higher dosages of opioids12. In fact, in England, there has been a 20% rise in opioid prescribing 
among IBD patients in the last 20 years1
Persistence of opioid use in previously opioid-naïve patients has been studied in patients 
prescribed opioids following various types of surgery. New persistent opioid use has been 
associated with different patient factors including behavioural and pain disorders
. 
13
. In addition, 
appreciating the dangers of prescribing narcotics for patients with IBD is an important step in the 
prevention of narcotic misuse10
 
. The aims of this study were 1) to determine the incidence of 
new persistent opioid use following IBD flares treated with oral corticosteroids, and 2) to 
identify patient factors associated with new persistent opioid use among opioid-naïve patients. 
Design 
Methods 
We performed a retrospective cohort analysis to identify the incidence of and associations 
with persistent opioid use following IBD flares treated with oral corticosteroid. 
Data sources 
We queried the Marketscan databases (Truven Health Analytics) between January 1st, 
2009 and December 31st, 2015 to identify patients with IBD diagnoses. The Marketscan 
databases contain health insurance claims of more than 230 million privately insured patients in 
the United States. The databases use rigorous methods to ensure that claims and enrolment data 
are complete, accurate, and reliable13. The databases have been accurately used to evaluate health 
outcomes in various clinical settings13. Within these databases we examined outpatient visits, 
inpatient admissions, services, enrolment tables, and pharmacy claims. Approval from the 
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Institutional Review Board at the University of Michigan was obtained to evaluate the data 
(HUM00127665).  
Study Sample 
The International Classification of Diseases, Ninth Revision, Clinical Modification 
diagnosis codes were used to identify patients 18 years or older with a diagnosis of IBD (555.x 
and 556.x). For the case definition of IBD we required at least 3 IBD codes on three different 
visit encounters14, or one IBD –related visit encounter associated with an IBD medication 
prescription (a 5-aminosalicylate, immunomodulator, or biologic), which were identified using 
National Drug Codes listed in pharmacy claims15. An IBD flare was defined by a new 
prescription for an oral systemic corticosteroid for at least 14 days not preceded by oral steroid 
use within the 120 days prior as is consistent with previously published literature16, 17. The 
reliability of this algorithm has been verified before with survey data16
We included patients who used an opioid around the time of the flare (within 30 days 
before or 14 days after the index flare). Only one index flare per patient was considered. 
Inclusion criteria required at least 12 months of continuous insurance enrolment before and after 
the index flare to accurately capture health comorbidities and outcome events. Patients were then 
classified prior to the index date into 3 groups: 1) chronic opioid users if they were prescribed at 
least 120 days of opioids within the year before the flare, or had received at least 3 opioid 
prescriptions within 90 days before the flare, 2) opioid-naïve users if they received no opioid 
prescriptions within the year preceding the flare, or 3) intermittent opioid users if they did not 
meet the criteria for chronic or naïve opioid users. Similar definitions have been previously used 
in the literature to categorize opioid users
.  
13
Outcomes: 
. The algorithm we used to select the study cohort is 
summarized in [Figure 1].  A complete list of opioid medications, 5-aminosalicylates, 
immunomodulators, biologics and corticosteroids can be found in Appendix 1. 
We abstracted age, gender, Charlson comorbidities, in addition to mental health 
conditions which included history of anxiety, depression, substance abuse (including opioid-type 
dependence), and other mental health disorders (including delirium, delusions, bipolar, manic, 
personality, sexual, and adjustment disorders) over the year prior to the index flare. We used an 
established algorithm, developed by Quan, et al.18, to abstract Charlson comorbidities (cancer, 
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cerebrovascular disease, congestive heart failure, chronic obstructive pulmonary disease, 
dementia, complicated diabetes mellitus , non-complicated diabetes mellitus, human 
immunodeficiency virus, cancer with metastasis , myocardial infarction, mild liver disease, 
moderate or severe liver disease, hemiplegia, peptic ulcer disease, peripheral vascular disease, 
renal disease, and rheumatological disease).  
The type of IBD was also abstracted (Crohn’s disease, ulcerative colitis, or indeterminate 
colitis); patients were labelled as indeterminate colitis if they had both Crohn’s and ulcerative 
colitis billing codes. We also abstracted concomitant IBD medication use at the time of the flare; 
for this we required at least 1 prescription of the medication within 3 months before the index 
flare. The primary endpoint was the development of persistent opioid use in opioid-naïve patients 
which was defined as opioid prescribed 90-365 days following the index IBD flare. We also 
calculated the median oral morphine equivalent dose per day for these prescriptions19
Statistical analysis: 
.  
Our analyses mainly focused on opioid naïve patients as they can be candidates for 
primary prevention strategies. Univariate unadjusted analyses were performed to compare 
demographics and baseline comorbidities between persistent and non-persistent opioid-naïve 
users. The Chi-square test and student t-test were used for categorical and normally distributed 
continuous variables, respectively. Independent predictors of persistent opioid use were 
identified using a Cox proportional hazard model accounting for the time to the event (time from 
index IBD flare to opioid persistence) while controlling for patient demographics and health 
comorbidities. Variables were selected for inclusion in the Cox model if they were statistically 
significant or approaching statistical significance (p≤0.1) in univariate analyses. To mitigate the 
impact of subsequent IBD flares (after the index flare) in estimating the hazard ratios for 
persistent opioid use, we incorporated subsequent flares as a time varying covariate in the model; 
this approach is known for improving the model’s goodness of fit20
 In sensitivity analyses for persistent opioid use in naive patients; we rebuilt the Cox 
model after excluding patients who underwent IBD-related surgery [Appendix 2] or were 
. Patients were censored at 
365 days following the index flare. A two-sided p value, with false discovery rate adjustment, ≤ 
0.05 was used to determine statistical significance. All analyses were performed using SAS 
software (version 9.4, SAS Institute Inc., Cary, NC, USA)  A
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hospitalized within the first 90 days following the index flare to remove possible confounding by 
indication (i.e. opioid prescribed following IBD surgery or hospitalization rather than IBD flare), 
and that patients who required surgery or hospitalization following the index flare might have 
had a more severe disease that required extended period of opioid use which may further inflate 
the rate of opioid persistence. In a third sensitivity analysis we created a cohort of pooled opioid-
naïve and intermittent opioid users to examine the independent association of previous 
intermittent opioid use with opioid persistence following an IBD flare. In a fourth sensitivity 
analysis, we examined the rate of opioid persistence after excluding patients who underwent 
surgical procedure codes for anaesthesia between 90 and 365 days after the index flare as they 
may have received opioid prescriptions for an acutely limited problem13. Likewise, we also 
examined persistence after excluding patients with multiple IBD flares other than the index flare. 
We also examined alternative definitions for opioid persistence as reported in the literature 
including 1) any opioid prescription 90-180 days following the index flare13, and 2) an opioid 
prescription 205-425 days following the index flare21. Lastly, we identified those who were 
prescribed at least 50 mg of oral morphine or equivalent anytime 90-365 days following the 
index flare; in this approach we accounted for overlapping prescriptions and calculated sums of 
oral morphine equivalents across prescribed days. This approach has been shown to improve 
identification of patients at high risk of overdosing22
 
. 
 Between 2009 and 2015, we identified a total of 605,862 patients with IBD of whom 
44.3% (268,418) received an opioid prescription during the study period. 15,119 patients met the 
inclusion criteria and used opioids around the time of the index flare [Figure 1]. Of those, 49.1% 
(n= 7,422) were chronic opioid users, 15.1% (n= 2,286) were intermittent opioid users, and 
35.8% (n= 5,411) were opioid-naïve patients. The average ages (± standard deviation) for 
chronic, intermittent, and naive opioid users were 50.6 (±14.7), 45.4 (±15.3), and 43.9 (±15.8), 
respectively. Females represented 63.5% (n=4,716), 61.3% (n=1,402), and 54.3% (n=2,939) of 
these cohorts, respectively [Table 1]. 
Results: 
Among opioid-naïve IBD patients, the risk of developing new persistent opioid use is 
35.0% (n=1,893) following an IBD flare that required a steroid prescription. The persistence 
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rates in the intermittent and chronic opioid users were 49.4%, and 73.7%, respectively. The 
median oral morphine equivalent/day for opioid naïve patients who persisted, accounting for 
overlapping prescriptions, was 72.0 mg (IQR: 60.0-90.0 mg). In univariate analyses, the opioid-
naive patients most likely to become persistent opioid users after a flare were more likely to have 
a history of chronic obstructive pulmonary disease, non-complicated diabetes mellitus, a 
rheumatological disease, or a mental health disorder including anxiety, depression, and substance 
abuse. The median (IQR) Charlson comorbidity index in both cohorts was 0 (0-2). Patients with 
Crohn’s disease, indeterminate colitis, and those on biologics were also more likely to become 
persistent opioid users. In contrast, patients on 5-aminosalicylate medications were less likely to 
become persistent opioid users (p<0.05) [Table 2]. 
In multivariable analysis, the independent predictors of new persistent opioid use are a 
history of depression (hazards ratio [HR] 1.29, 95%CI 1.13-1.47), substance abuse (HR 1.36, 
95% CI 1.20-1.54), chronic obstructive pulmonary disease (HR 1.17, 95% CI 1.04-1.30), as well 
as Crohn’s disease (HR 1.26, 95% CI 1.14-1.40) and indeterminate colitis (HR 1.60, 95% CI 
1.36-1.88) compared with ulcerative colitis. 5-aminosalicylate use at the time of the flare was 
protective against opioid persistence [Table 3]. 
In a sensitivity analysis excluding patients with a hospitalization or IBD-related surgery 
occurring in the first 90 days following the index flare (n= 1,034), persistent opioid users 
represented 32.7% (n=1,433) of 4,377 opioid naïve users. Independent predictors of persistent 
opioid use remained similar to the findings of the primary analysis other than 5-aminosalicylates 
which was no longer a predictor [Appendix 3]. When opioid naïve and intermittent opioid users 
were pooled together, prior intermittent opioid use was an independent predictor of future opioid 
persistence following an IBD flare (HR 1.51, 95% CI 1.40-1.63) [Appendix 4]. When we 
excluded patients who underwent surgery between 90-365 days following the index flare 
(n=1,253), the persistence rate for opioid naïve patients was 25.4%. After excluding patients who 
developed multiple flares other than the index flare (n=402), persisted opioid users represented 
35.9% of the opioid naïve patients (compared to 35.8% without excluding these patients).  
Examining the alternative definitions of opioid persistence (opioid prescribed 90-180 and 205-
425 after the index flare) revealed that 22.8 % (n=1,235) and 16.7 % (n=906) of opioid naïve 
patients persisted, respectively. We also found that 18.8% (n= 1,015) of opioid naïve patients 
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used at least 1 prescription of 50mg of oral morphine equivalents or more 90 to 365 days 
following the index flare. 
 
This is the first study to examine the risk of developing new persistent opioid use in IBD 
patients. Among a United Stated cohort of 15,119 patients who used opioids around the time of 
an IBD flare, 35.8% were opioid-naïve patients. Of the opioid-naïve users, more than one-third 
(35.0%) became persistent opioid users. This is an important finding because it highlights the 
significance and the magnitude of new persistent opioid use as an underappreciated iatrogenic 
complication following an IBD flare. More than half of these patients (n=1,015; 53.6%) used at 
least one prescription of 50mg of oral morphine equivalents or more which has been previously 
shown to be associated with 3.7 to 8.9-fold increase in overdose risk
Discussion: 
23
This new data is complimentary to currently available literature on opioids in IBD. It has 
been well established that the prevalence of opioid use in IBD is rising, at is in the general 
United States population
.  
24
. In a landmark paper, Targownik, et al. investigated heavy opioid use 
in IBD patients and reported that individuals with IBD are 3 times more likely to become heavy 
opioid users compared with their matched controls. Heavy opioid use was also significantly 
associated with mortality12
We also demonstrated that the predictors of new persistent opioid use include a history of 
depression, substance abuse, and chronic obstructive pulmonary disease. Patients with IBD and 
chronic obstructive pulmonary disease are at particularly high risk for complications from opioid 
use. A recent study demonstrating a higher mortality among chronic obstructive pulmonary 
disease patients who use opioids
. Hence, this is an essential topic to address proactively in IBD care.  
25
. These predictors are also similar to a great extent with 
previous surgical literature evaluating predictors of new persistent opioid use following surgical 
procedures13. Mental health disorders are also known predictors of opioid use and misuse10. A 
recent study of Veterans with structural and unexplained gastrointestinal symptoms also 
identified the higher likelihood of opioid prescriptions among patients with comorbid psychiatric 
disease26. Substance abuse and other mental health disorders often co-exist. The link is likely 
multifactorial, though theories correlating among these disorders include substance abuse 
disorder related psychiatric symptoms and substance abuse as a result of self-medicating27.  
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Further, it’s important to note that there is a known association between psychiatric disease and 
active IBD, which could potentially increase the likelihood of opioid seeking behaviour28
Persistent opioid use was also independently associated with Crohn’s disease and 
indeterminate colitis compared with ulcerative colitis. The pain-predominant symptoms 
impacting patients with Crohn’s disease as compared to ulcerative colitis likely contributes to 
this association. Additionally, patients on a 5-aminosalicylate medication were less likely to 
become persistent opioid users. This association could be driven by the increased use of 5-
aminosalicylates in ulcerative colitis and the milder severity of the underlying IBD disease in 
patients on a 5-aminosalicylate compared to patients using immunomodulators or biologics. A 
previous case-control study identifying factors associated with opioid use in IBD patients 
showed similar associations such as depression, anxiety, and substance abuse
. 
29
Management strategies for chronic pain are a primary focus in the midst of the opioid 
epidemic
.  These findings 
can be helpful in risk stratifying patients, weighing analgesic choices and alternatives, and 
providing counselling for opioid naïve patients when choosing an acute pain therapy for an IBD 
flare.   
18, 30-32
. However, no clear consensus on guidelines regarding acute pain management 
surrounding an IBD flare have been investigated. A recent study showed that IBD patients are 
more likely to be prescribed narcotics in acute care settings such as emergency departments, 
urgent care settings, and surgical outpatient follow up visits33. Alternatives to opioids need to be 
considered in the management of pain related to IBD, including neuroleptic medications and 
psychotherapy34, 35
 The limitations of this study are inherent to any large administrative databases; while 
these databases excel in evaluating global trends and patterns, they lack granularity. For instance, 
we were not able to determine the severity of IBD in each patient and stratify the patients 
accordingly. Likewise, other disease related issues such as anatomical location, perianal disease, 
age at onset, and tobacco use cannot be accurately measured in an administrative database. We 
are not able to further characterize opioid prescribers’ specialty, institutional factors, such as 
differentiating urban and rural settings, or account for opioid diversion. Databases are subject to 
data entry errors which may lead to inaccurate billing codes. The Marketscan databases use 
. As such, further studies exploring the management of acute pain in IBD 
patients are warranted to address this need. 
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rigorous methods to ensure that claims and enrolment data are complete, accurate, and reliable13. 
The databases have been accurately used to evaluate health outcomes in various clinical 
settings13
Persistent opioid use might have resulted from other factors such as IBD-related surgeries 
leading to extended opioid requirements
.  
36
. To address this issue, in a sensitivity analysis, we 
excluded patients who underwent IBD-related surgeries around the index flare (0-90 days). We 
found no major difference in the incidence of persistent opioid use or identified predictors. While 
we acknowledge the myriad of treatment options available for treating IBD flares including 
biologics, immunomodulators, and parenteral steroid use, we only investigated patients who 
were treated with oral steroids for an IBD flare as consistent with previously published 
literature16 for the simplicity of approach. Indeed, a recent study demonstrated that despite the 
availability of new multiple treatment options for IBD disease, the utilization of corticosteroids 
has remained constant with no decline through the years 2003 to 201133
Despite these limitations, this study of 15,119 privately insured patients in the United 
States with opioid use around the time of steroid-defined flares underscores the significance of 
persistent opioid use following an IBD flare as an underappreciated iatrogenic complication. The 
study also identifies several patient factors associated with high risk of persistent opioid use. 
. In our analyses, we also 
controlled for the concomitant use of these agents at the time of the flare. It is uncertain whether 
the findings of this study are generalizable to patients treated for flares without oral 
corticosteroids. Likewise, as the population of this study is based on commercial insurance 
databases, the findings of this study are not necessarily generalizable to the uninsured, 
underinsured, or the general Medicare population. 
In conclusion, new persistent opioid use is common in the United States following an 
IBD flare treated with corticosteroids. Persistent opioid use is increased among those with mental 
health disorders, chronic obstructive pulmonary disease, prior opioid use, and Crohn’s disease or 
indeterminate colitis, compared with ulcerative colitis. These findings can be helpful in risk-
stratifying patients when choosing an acute pain therapy and guiding counselling of patients 
before prescribing opioids to opioid-naïve patients experiencing an IBD flare. Further studies are 
warranted to investigate the physician-level and health-system level risk factors associated with 
new persistent opioid use. 
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Table 1: Opioid Users Around the Initial IBD Flare by Type  
Variable Opioid User by Type 
 
Chronic Intermittent Naive 
Total (%) 7,422 (49.1) 2,286 (15.1) 5,411 (35.8) 
Females (%) 4,716 (63.5) 1,402 (61.3) 2,939 (54.3) 
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Age (mean ± SD) 50.6 (±14.7) 45.4 (±15.3) 43.9 (±15.8) 
SD (standard deviation) 
 
Table 2: Univariate Comparison Between Persistent and Non-Persistent Opioid Users Among 
Opioid Naïve Patients 
Variable 
Persisted 
Opioid 
Users 
Non-
Persisted 
Users 
Adjusted p-
value* 
Demographics 
Total (%) 1,893 (35.0) 3,518 (65.0) - 
Age, Mean (SD) 44.0 (15.6) 43.9 (16.0) 0.88 
Female 1,060 (56.1) 1,867 (53.3) 0.15 
Region  
Northeast 
Northcentral 
South 
West 
Unknown 
 
350 (18.5) 
436 (23) 
737 (38.9) 
312 (16.5) 
58 (3.1) 
 
686 (19.5) 
882 (25.1) 
1,283 (36.5) 
586 (16.7) 
81 (2.3) 
 
0.16 
 
Type of ID disease 
Crohn’s 
Ulcerative Colitis 
Indeterminate Colitis 
1,137 (60.1) 
558 (29.5) 
198 (10.5) 
1,939 (55.1) 
1320 (37.5) 
259 (7.4) 
0.02 
 
Comorbidities 
Cancer 173 (9.1) 292 (8.3) 0.36 
Cerebrovascular disease 122 (6.4) 194 (5.5) 0.22 
Congestive Heart Failure 95 (5) 136 (3.9) 0.10 
Chronic obstructive pulmonary disease 438 (23.1) 665 (18.9) 0.02 
Dementia 6 (0.3) 12 (0.3) 0.90 
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Complicated Diabetes mellitus 45 (2.4) 71 (2) 0.44 
Non-Complicated Diabetes mellitus 215 (11.4) 329 (9.4) 0.05 
Human immunodeficiency virus 5 (0.3) 7 (0.2) 0.71 
Cancer with metastasis  45 (2.4) 80 (2.3) 0.88 
Myocardial Infarction 43 (2.3) 54 (1.5) 0.10 
Mild liver disease 216 (11.4) 395 (11.2) 0.89 
Moderate or severe liver disease 22 (1.2) 51 (1.4) 0.44 
Hemiplegia 15 (0.8) 14 (0.4) 0.11 
Peptic ulcer disease 59 (3.1) 123 (3.5) 0.52 
Peripheral vascular disease 141 (7.4) 219 (6.2) 0.14 
Renal disease 78 (4.1) 121 (3.4) 0.27 
Rheumatological disease 120 (6.3) 168 (4.8) 0.03 
Mental health disorders 
Anxiety 416 (22) 599 (17) 0.02 
Depression 311 (16.4) 377 (10.7) 0.02 
Substance abuse 311 (16.4) 384 (10.9) 0.02 
Other mental disorders 172 (9.1) 236 (6.7) 0.02 
IBD related medications 
5-Acetylsalicylic acid 598 (31.6) 1283 (36.5) 0.02 
Immunomodulators 93 (4.9) 169 (4.8) 0.90 
Biologics 81 (4.3) 108 (3.1) 0.05 
Budesonide 15 (0.8) 26 (0.7) 0.89 
* False discovery rate (FDR) adjusted p values 
SD (standard deviation) 
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Table 3: Survival Model for Predictors of Persistent Opioid Users Among Opioid Naïve 
Patients.  
Predictors Hazard Ratio (95% CI) P-value** 
Depression 1.29 (1.13-1.47) 0.02 
Substance abuse 1.36 (1.20-1.54) 0.02 
Chronic obstructive pulmonary 
disease 
1.17 (1.04-1.3) 0.03 
Crohn’s disease vs UC 1.26 (1.14-1.4) 0.02 
Indeterminate Colitis vs UC 1.60 (1.36-1.88) 0.02 
5-aminosalicylate use 0.88 (0.80-0.97) 0.03 
Subsequent flares* 3.85 (2.79-5.32) 0.02 
Anxiety 1.12 (1.00-1.26) 0.11 
Other mental health disorders 1.16 (0.99-1.37) 0.12 
Non-Complicated Diabetes mellitus 1.14 (0.98-1.32) 0.13 
Rheumatological disease 1.17 (0.97-1.42) 0.14 
Myocardial Infarction 1.21 (0.89-1.66) 0.30 
Congestive Heart Failure 1.11 (0.89-1.39) 0.42 
Biologic use 1.12 (0.89-1.40) 0.42 
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Appendix 1: List of Medications Abstracted 
IBD related medications Oral systemic steroids Opioids 
5-ASA 
Mesalamine 
Olsalazine 
Balsalazide 
Sulfasalazine 
Immunomodulator 
Methotrexate 
Cyclosporine 
Azathioprine 
Mercaptopurine 
Biologics 
Infliximab 
Adalimumab 
Certolizumab 
Natalizumab 
Vedolizumab 
Ustekinumab 
Golimumab  
Non-systemic steroid 
Budesonide 
Betamethasone 
Dexamethasone 
Methylprednisolone 
Triamcinolone 
Prednisone 
Prednisolone 
Hydrocortisone 
Cortisone 
Butorphanol 
Buprenorphine 
Methadone 
Hydrocodone 
Oxycodone 
Tramadol 
Codeine 
Hydromorphone 
Meperidine 
Morphine 
Fentanyl 
Dihydrocodeine 
Pentazocine 
Oxymorphone 
Tapentadol 
Levorphanol 
Propoxyphene 
 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
Appendix 2: List of IBD related surgeries and corresponding codes 
Procedure Name ICD9-CM Procedure Code Corresponding CPT codes 
Small Intestinal Resection 45.6-45.62 44157, 44158, 44211, 45113, 
44141, 44143, 44144, 44150, 
44206, 44210, 44155, 44212, 
44146, 44140, 44160, 44204, 
44205, 44145, 44120, 44125, 
44202, 37197, 45110, 45111, 
45112, 45114, 45119, 45123, 
45136, 44320, 45000, 45005, 
45020, 46040, 46045, 45800, 
45820, 46030, 57305, 57308, 
46060, 46706, 46020 
 
Colonic Resection 45.71-45.76, 45.79, 45.8 
Small Intestinal Fistula Closure 46.74 
Large Intestinal Fistula Closure 46.76 
Rectal Surgery 48.49, 48.5, 48.61-48.65, 48.69 
Rectal Fistula Closure 48.73 
Perirectal Fistula Closure 48.93 
Perianal Abscess Drainage 49.01 
Anal Fistula Repair 49.11-49.12, 49.73 
Repair of Fistula between 
Intestines and Urinary System 57.83, 58.43 
Repair of Fistula between 
Intestines and Vagina 70.72-70.74 
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Appendix 3: Sensitivity analysis -  Survival Model for Predictors of Persistent 
Opioid Users Among Opioid Naïve Patients excluding patients with 
hospitalizations or IBD related surgeries* 
Predictors Hazard Ratio (95% CI) Adjusted P-value*** 
Depression 1.40 (1.21-1.63) 0.02 
Substance abuse 1.42 (1.23-1.64) 0.02 
Chronic obstructive pulmonary disease 1.19 (1.05-1.35) 0.03 
Crohn’s vs UC 1.32 (1.17-1.48) 0.02 
Indeterminate Colitis vs UC 1.52 (1.24-1.86) 0.02 
Subsequent flares** 3.75 (2.63-5.35) 0.02 
Rheumatological disease 1.26 (1.03-1.55) 0.07 
5-ASA use 0.89 (0.80-1.00) 0.09 
Anxiety 1.13 (0.99-1.29) 0.12 
Non-Complicated Diabetes mellitus 1.15 (0.97-1.37) 0.15 
Myocardial Infarction 1.32 (0.91-1.91) 0.20 
Other mental health disorders 1.13 (0.93-1.37) 0.28 
Gender 1.07 (0.96-1.19) 0.32 
Cerebrovascular disease 1.13 (0.92-1.40) 0.32 
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Appendix 4: Predictors of persistent opioid use in a pooled cohort 
of naïve and intermittent users 
Variable Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
P-values* 
Depression 1.115 1.004 1.238 0.09 
Anxiety 1.124 1.025 1.232 0.03 
Substance abuse 1.251 1.134 1.379 0.02 
Hemiplegia 1.598 1.111 2.297 0.03 
Intermittent vs naïve 1.511 1.402 1.628 0.02 
Indeterminate vs ulcerative colitis 1.442 1.263 1.646 0.02 
Crohn’s vs ulcerative colitis 1.190 1.097 1.292 0.02 
DM, non-complicated 1.138 1.017 1.275 0.06 
Rheumatological disease 1.167 1.015 1.341 0.07 
5-asa 0.914 0.844 0.989 0.06 
Subsequent Flares** 4.115 3.174 5.334 0.02 
Other mental disorders 1.125 0.992 1.276 0.12 
CHF 1.175 0.987 1.400 0.12 
Females 1.069 0.993 1.152 0.13 
Biologics use 1.166 0.981 1.385 0.13 
COPD 1.041 0.954 1.136 0.43 
MI 1.013 0.783 1.309 0.94 
Immunomodulators use 1.005 0.854 1.183 0.95 
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Appendix 4: Predictors of persistent opioid use in a pooled cohort 
of naïve and intermittent users 
Variable Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
P-values* 
* subsequent flares were adjusted for as a time varying covariate in the survival model 
UC: ulcerative colitis 5-ASA: 5-Acetylsalicylic acid 
** False discovery rate (FDR) adjusted p-value 
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Figure 1: Patients selection algorithm 
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